{
    "id": "36f1b227-c566-fc71-41a9-7c02f7076ee5",
    "indications": "Multiple Myeloma-Palliative Treatment\n                  \n                  IVRA is indicated for the palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate.",
    "contraindications": "Recommended dosage is 16 mg/m 2 administered intravenously over 15 to 20 minutes at 2-week intervals for 4 doses, then, after adequate recovery from toxicity, at 4-week intervals. ( 2.2 ) See full prescribing information for preparation and administration instructions. ( 2.3 )",
    "warningsAndPrecautions": "How Supplied\n                  \n                  IVRA (melphalan) injection is a clear colorless to yellow solution supplied in a carton containing one 90 mg/mL amber glass multiple-dose vial for dilution. (NDC 60505-6414-1).\n                  \n                     Storage and Handling\n                  \n                  Store IVRA refrigerated at 2°C to 8°C (36°F to 46°F). IVRA is light sensitive. Retain in original carton when not in use.\n                  IVRA is a hazardous drug1. Follow special handling and disposal procedures1.",
    "adverseReactions": "IVRA is contraindicated in patients with a history of severe hypersensitivity to melphalan. Reactions have included anaphylaxis [see Warnings and Precautions (5.4)].",
    "ingredients": [
        {
            "name": "MELPHALAN HYDROCHLORIDE",
            "code": "1VXP4V453T"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "MONOTHIOGLYCEROL",
            "code": "AAO1P0WSXJ"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        }
    ],
    "organization": "Apotex Corp",
    "name": "IVRA",
    "effectiveTime": "20250509"
}